Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit

Plaintiff Lawyers: Ranbaxy ‘Facing Liabilities In The Billions’

Executive Summary

A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.

You may also be interested in...



What’s Next? Five Things To Look Out For In January

Sun Pharma’s key antitrust trial kicks off and Lannett awaits word from the US FDA for its generic Advair filing during a busy first month of 2022, which also features updates from the annual J.P. Morgan Health Care Conference.

FDA Employees Were ‘Granting Approval Without Knowing Why,’ Judge Rules In Ranbaxy Case

But court finds FDA has authority to correct its mistakes and revoke Ranbaxy’s tentative ANDA approvals

Ranbaxy Cleared To Launch Diovan Generic In U.S. With Exclusivity

Ranbaxy Laboratories is free to launch its generic version of the Novartis drug Diovan (valsartan) for treating high blood pressure in the U.S. after gaining U.S. FDA approval.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel